Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LYT-100 in Breast Cancer-Related Lymphoedema
NCT04243837Phase 2Terminated
- Sponsor
- PureTech Health
- Start
- Mar 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in breast cancer-related lymphedema (BCRL) comparing LYT-100 with Placebo (2 arms). Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (TEAEs) at 6 months. Started Mar 2020; status: terminated.
02
Drugs
deupirfenidone
03
Conditions
breast cancer-related lymphedema (BCRL)
Beyond the preview
Go deeper on NCT04243837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04243837.